The estimated Net Worth of Robert K Zeldin is at least $435 Tysiąc dollars as of 14 January 2024. Dr Zeldin owns over 37,500 units of MeiraGTx plc stock worth over $434,637 and over the last 6 years he sold MGTX stock worth over $0.
Sign up
Dr D MGTX stock SEC Form 4 insiders trading
Dr has made over 4 trades of the MeiraGTx plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 37,500 units of MGTX stock worth $156,000 on 14 January 2024.
The largest trade he's ever made was exercising 75,000 units of MeiraGTx plc stock on 14 January 2023 worth over $312,000. On average, Dr trades about 13,864 units every 54 days since 2018. As of 14 January 2024 he still owns at least 104,480 units of MeiraGTx plc stock.
You can see the complete history of Dr Zeldin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Robert K. Zeldin M.D. biography
Dr. Robert K. Zeldin M.D. is the Chief Medical Officer at MeiraGTx plc.
How old is Dr D?
Dr D is 58, he's been the Chief Medical Officer of MeiraGTx plc since . There are 8 older and 8 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
What's Dr D's mailing address?
Robert's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Insiders trading at MeiraGTx plc
Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus oraz Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.
What does MeiraGTx plc do?
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
What does MeiraGTx plc's logo look like?
Complete history of Dr Zeldin stock trades at Acceleron Pharma Inc, MeiraGTx plc oraz Immunovant Inc
MeiraGTx plc executives and stock owners
MeiraGTx plc executives and other stock owners filed with the SEC include:
-
Alexandria Forbes,
President, Chief Executive Officer, Director -
Richard Giroux,
Chief Financial Officer, Chief Operating Officer -
Dr. Alexandria Forbes,
CEO, Pres & Director -
Martin Indyk,
Independent Director -
Richard Brian Giroux B.A.,
COO & CFO -
Stuart Naylor,
Chief Development Officer -
Dr. Stuart Naylor Ph.D.,
Chief Devel. Officer -
Nicole Seligman,
Independent Director -
Keith Harris,
Independent Chairman of the Board -
Neil Mendoza,
Independent Director -
Joel Marcus,
Independent Director -
Arnold Levine,
Independent Director -
Thomas Shenk,
Independent Director -
Ellen Hukkelhoven,
Independent Director -
Elizabeth Broder,
Investor Relations -
Dr. Robert K. Zeldin M.D.,
Chief Medical Officer -
Dr. Alastair Leighton,
Sr. VP of Manufacturing & Supply Chain -
Tim Randall,
Sr. VP of Risk & Internal Controls -
Joel P. Brooks,
Sr. VP of Fin. -
Christine Elise Sheehy,
Sr. VP of Global Integration -
Dr. Michel Michaelides M.D.,
Head of Clinical Ophthalmology -
Robert J. Wollin J.D.,
Gen. Counsel & Sec. -
& Johnson Innovation Jjdc...,
10% owner -
Advisors Llcperceptive Life...,
-
Katherine Breedis,
Chief Financial Officer -
Life Sciences Master Fund L...,
-
Bruce Gottlieb,
General Counsel -
Advisors Llcedelman Joseph ...,
-
Debra Yu,
-
Robert K Zeldin,
CHIEF MEDICAL OFFICER -
Robert J Wollin,
GENERAL COUNSEL AND SECRETARY